Zhang Yiqun, Kwok-Shing Ng Patrick, Kucherlapati Melanie, Chen Fengju, Liu Yuexin, Tsang Yiu Huen, de Velasco Guillermo, Jeong Kang Jin, Akbani Rehan, Hadjipanayis Angela, Pantazi Angeliki, Bristow Christopher A, Lee Eunjung, Mahadeshwar Harshad S, Tang Jiabin, Zhang Jianhua, Yang Lixing, Seth Sahil, Lee Semin, Ren Xiaojia, Song Xingzhi, Sun Huandong, Seidman Jonathan, Luquette Lovelace J, Xi Ruibin, Chin Lynda, Protopopov Alexei, Westbrook Thomas F, Shelley Carl Simon, Choueiri Toni K, Ittmann Michael, Van Waes Carter, Weinstein John N, Liang Han, Henske Elizabeth P, Godwin Andrew K, Park Peter J, Kucherlapati Raju, Scott Kenneth L, Mills Gordon B, Kwiatkowski David J, Creighton Chad J
Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX 77030, USA.
Department of Systems Biology, University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA; Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Cancer Cell. 2017 Jun 12;31(6):820-832.e3. doi: 10.1016/j.ccell.2017.04.013. Epub 2017 May 18.
Molecular alterations involving the PI3K/AKT/mTOR pathway (including mutation, copy number, protein, or RNA) were examined across 11,219 human cancers representing 32 major types. Within specific mutated genes, frequency, mutation hotspot residues, in silico predictions, and functional assays were all informative in distinguishing the subset of genetic variants more likely to have functional relevance. Multiple oncogenic pathways including PI3K/AKT/mTOR converged on similar sets of downstream transcriptional targets. In addition to mutation, structural variations and partial copy losses involving PTEN and STK11 showed evidence for having functional relevance. A substantial fraction of cancers showed high mTOR pathway activity without an associated canonical genetic or genomic alteration, including cancers harboring IDH1 or VHL mutations, suggesting multiple mechanisms for pathway activation.
在代表32种主要类型的11219例人类癌症中,检测了涉及PI3K/AKT/mTOR途径的分子改变(包括突变、拷贝数、蛋白质或RNA)。在特定的突变基因中,频率、突变热点残基、计算机模拟预测和功能测定在区分更可能具有功能相关性的遗传变异子集方面都具有参考价值。包括PI3K/AKT/mTOR在内的多个致癌途径汇聚于相似的下游转录靶点集。除了突变,涉及PTEN和STK11的结构变异和部分拷贝缺失也显示出具有功能相关性的证据。相当一部分癌症显示出高mTOR途径活性,但没有相关的典型遗传或基因组改变,包括携带IDH1或VHL突变的癌症,这表明途径激活存在多种机制。